Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We conducted a randomized trial of the treatment of multiple myeloma with high-dose chemotherapy followed by either one or two successive autologous stem-cell transplantations. METHODS: At the time of diagnosis, 399 previously untreated patients under the age of 60 years were randomly assigned to receive a single or double transplant. RESULTS: A complete or a very good partial response was achieved by 42 percent of patients in the single-transplant group and 50 percent of patients in the double-transplant group (P=0.10). The probability of surviving event-free for seven years after the diagnosis was 10 percent in the single-transplant group and 20 percent in the double-transplant group (P=0.03). The estimated overall seven-year survival rate was 21 percent in the single-transplant group and 42 percent in the double-transplant group (P=0.01). Among patients who did not have a very good partial response within three months after one transplantation, the probability of surviving seven years was 11 percent in the single-transplant group and 43 percent in the double-transplant group (P<0.001). Four factors were significantly related to survival: base-line serum levels of beta2-microglobulin (P<0.01) and lactate dehydrogenase (P<0.01), age (P<0.05), and treatment group (P<0.01). CONCLUSIONS: As compared with a single autologous stem-cell transplantation after high-dose chemotherapy, double transplantation improves overall survival among patients with myeloma, especially those who do not have a very good partial response after undergoing one transplantation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In earlier randomized trials, an improvement in OS was seen in two studies,132,133 but other studies failed to show such an improvement.134,135”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [132]
Citations
Cites
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
Richardson, P. G., Barlogie, B., Berenson, J., Singhal, S., Jagannath, S., Irwin, D., Rajkumar, S. V., Srkalovic, G., Alsina, M., Alexanian, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030288 · Cited by 2,632
Antitumor Activity of Thalidomide in Refractory Multiple Myeloma
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199911183412102 · Cited by 2,575
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Self-citationHigh-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022340 · Cited by 1,768
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Moreau, P. (2002) · Blood · doi:10.1182/blood.v99.3.731 · Cited by 564
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
(1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.12.3832 · Cited by 433
INTENSIVE TREATMENT OF MULTIPLE MYELOMA AND CRITERIA FOR COMPLETE REMISSION
Gore, M. E., Viner, C., Meldrum, M., Bell, J., Milan, S., Zuiable, A., Slevin, M., Selby, P. J., Clark, P. I., Millar, B., et al. (1989) · The Lancet · doi:10.1016/s0140-6736(89)91548-1 · Cited by 190
Research works printed but not linked: 7
- Barlogie B, 1991, Bone Marrow Transplant, 7, 71
- Fermand J-P, 1999, Blood, 94, 396a
- Blade J, 2001, Blood, 98, 815a
- Palumbo A, 2001, Blood, 98, 849a
- Fermand J-P, 2001, Blood, 98, 815a
- Richardson P, 2002, Blood, 100, 104a
- Sirohi B, 2002, Bone Marrow Transplant, 29, S12
Cited by
Items 701–800 of 987
Maiolino, Â., Crusoé, E. D. Q., Martınez, G., Braga, W. M. T., de Farias, D. L. C., Bittencourt, R., Neto, J. V. P., Ribeiro, G., Bernardo, W. M., Tristão, L. S., et al. (2022) · Hematology Transfusion and Cell Therapy · doi:10.1016/j.htct.2022.06.003 · Cited by 4
When to recommend a second autograft in patients with relapsed myeloma?
Ziogas, D. C., Terpos, E., & Dimopoulos, M. A. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2016.1246729 · Cited by 5
Sauer, S., Pavel, P., Schmitt, A., Cremer, M., Kriegsmann, M., Bruckner, T. M., Jordan, K., Wuchter, P., Müller‐Tidow, C., & Kriegsmann, K. (2020) · BMC Cancer · doi:10.1186/s12885-020-06873-7 · Cited by 4
Lin, C., & Sung, Y. (2009) · Hematology/Oncology and Stem Cell Therapy · doi:10.1016/s1658-3876(09)50006-4 · Cited by 4
Total therapy-based treatment for multiple myeloma—a single center experience
Magen‐Nativ, H., Ram, R., Yeshurun, M., Gafter‐Gvili, A., Raanani, P., & Shpilberg, O. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0767-x · Cited by 4
Targeted treatments to improve stem cell outcome: old and new drugs
Raab, M., Breitkreutz, I., & Anderson, K. C. (2007) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705829 · Cited by 5
Kobayashi, T., Kuroda, J., Fuchida, S., Murakami, S., Hatsuse, M., Okano, A., Iwai, T., Tsutsumi, Y., Kamitsuji, Y., Akaogi, T., et al. (2013) · Internal Medicine · doi:10.2169/internalmedicine.52.9385 · Cited by 4
Bortezomib: the evidence of its clinical impact in multiple myeloma
Journal, C. (2006) · Core evidence · doi:10.2147/ce.s7452 · Cited by 4
“It has also been shown that two successive SCTs significantly improves OS compared with single SCT following HDT (Attal et al. 2003).”
Quetglas, E. G., Perea, J. R. A., & Villamediana, R. L. (2008) · Medicina Clínica · doi:10.1157/13120342 · Cited by 6
Teng, C. J., Yu, J.-T., Cheng, S., Yang, Y., Chang, K., & Hwang, W.-L. (2016) · Journal of Blood Medicine · doi:10.2147/jbm.s95679 · Cited by 4
Charlot-Lambrecht, I., Salmon, J.-H., Gagneux-Lemoussu, L., Brochot, P., & Eschard, J. (2011) · EMC - Appareil locomoteur · doi:10.1016/s0246-0521(11)57251-1 · Cited by 4
Multiple Myeloma and Related Disorders
Rajkumar, S. V., & Dispenzieri, A. A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50114-7 · Cited by 4
Bortezomib in the Upfront Treatment of Multiple Myeloma
Miguel, J. F. S., & Mateos, M. (2010) · Springer eBooks · doi:10.1007/978-3-7643-8948-2_4 · Cited by 4
Current Therapies for Multiple Myeloma
Tariman, J. D. (2007) · Journal of Infusion Nursing · doi:10.1097/01.nan.0000264715.28005.ea · Cited by 4
Mahou, S. E., Jamard, B., Constantin, A., Cantagrel, A. G., Mazières, B., Laroche, M., Attal, M., & Arnaud, C. (2005) · Clinical Rheumatology · doi:10.1007/s10067-005-1151-4 · Cited by 4
“A second study of 399 subjects under the age of 60 years, divided into two arms receiving either single or double transplant, reported improved overall survival in favour of tandem transplant (46 vs 26%, p--0.02) [ 57 ].”
BackgroundSelf-citationIntegrating Novel Therapies in the Transplant Paradigm
Harousseau, J. (2009) · The Cancer Journal · doi:10.1097/ppo.0b013e3181c51ca3 · Cited by 4
Self-citationPharmacotherapy of multiple myeloma
Hussein, M. A. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.6.767 · Cited by 4
“[89], the single transplant arm received the identical regimen reported by Moreau et al.”
BackgroundMethodResultInfluentialJungová, A., Vokurka, S., Schutzova, M., Steinerová, K., Mohammadová, L., Karas, M., Lysák, D., & Jindra, P. (2018) · Neoplasma · doi:10.4149/neo_2018_170511n346 · Cited by 4
“The latest recommendations advise a therapy followed by consolidation [9] and alternatively a maintaining therapy [4, 7].”
BackgroundStem cell transplantation in multiple myeloma
Björkstrand, B. (2005) · Hematology · doi:10.1080/10245330512331389809 · Cited by 4
“In the French IFM94-study [6], 399 previously untreated patients were randomized at diagnosis to receive either single or double ASCT following induction treatment.”
MethodFriedman, J. D., Khoury, H. J., Adkins, D., Devine, S. M., Nervi, B., Edwards, T., DiPersio, J. F., & Vij, R. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704937 · Cited by 4
Treatment Paradigms for the Newly Diagnosed Patient With Multiple Myeloma
Greipp, P. R. (2005) · Seminars in Hematology · doi:10.1053/j.seminhematol.2005.10.002 · Cited by 4
Solovev, M. V., Менделеева, Л. П., Pokrovskaya, O. S., Nareyko, M. V., Фирсова, М. В., Galtseva, I. V., Davydova, Y. O., Михайлович, К. Н., Kuzmina, L. A., Гемджян, Э. Г., et al. (2017) · Terapevticheskii arkhiv · doi:10.17116/terarkh201789725-31 · Cited by 4
Moreau, P., Hulin, C., Talbot, A., Demarquette, H., Caillot, L., Chalopin, T., Bobin, A., Manier, S., Leleu, X. P., Karlin, L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01387-6 · Cited by 4
“The IFM was the fi rst to conduct a prospective trial, IFM 94-01, comparing single versus tandem HDT [7].”
Self-citationBorst, N., Ihorst, G., Wenger, S., Räder, J., Wäsch, R., Engelhardt, M. M., & Rassner, M. P. (2024) · Cancers · doi:10.3390/cancers16234090 · Cited by 4
Choate, J. D., & Snyder, E. L. (2011) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2011.06.008 · Cited by 3
“two successive autologous transplants [9], and double transplants had become standard treatment for myeloma”
BackgroundMactier, C. E., & Islam, M. S. (2012) · Oncology Reviews · doi:10.4081/oncol.2012.e14 · Cited by 3
Martino, M. V., Recchia, A. G., Console, G., Gentile, M., Cimminiello, M., Gallo, G. A., Ferreri, A., Naso, V., Irrera, G., Messina, G., et al. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1387050 · Cited by 3
Lin, Y., Park, Y. M., Khanal, A., Campbell‐Lee, S. A., Liu, L., Chen, Z., Patel, P. R., Vidanovic, V., Sweiss, K. I., Irene, G., et al. (2022) · European Journal Of Haematology · doi:10.1111/ejh.13856 · Cited by 3
“Autologous transplantation of hematopoietic stem cells from mobilized peripheral blood (PB) after high-dose chemotherapy is the standard of care for patients with hematologic malignancies such as multiple myeloma (MM), Hodgkin's lymphoma and non-Hodgkin's lymphoma (NHL).(1,2) In order to have timely blood cell reconst…”
BackgroundCohen, I., Vaxman, I., & Gertz, M. A. (2024) · Acta Haematologica · doi:10.1159/000539225 · Cited by 6
“Tandem transplantation was shown to have a clear OS bene fi t over a single transplantation in a randomized-controlled trial of 399 patients under the age of 60, especially for patients not achieving VGPR after the fi rst transplant [36].”
Perrot, A. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104262 · Cited by 3
Die Bedeutung der Stammzelltherapie in der Hämatologie und Onkologie
Marks, R., & Finke, J. (2006) · Der Internist · doi:10.1007/s00108-006-1601-3 · Cited by 3
Haas, R. R., Bruns, I., Kobbe, G., & Fenk, R. R. (2011) · Recent results in cancer research/Recent Results in Cancer Research · doi:10.1007/978-3-540-85772-3_10 · Cited by 3
Role of bortezomib for the treatment of previously untreated multiple myeloma
Mateos, M. (2008) · Expert Review of Hematology · doi:10.1586/17474086.1.1.17 · Cited by 3
Autologous Hematopoietic Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
McCarthy, P. L., Owzar, K., & Hahn, T. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.2 · Cited by 3
Role of allogeneic stem cell transplantation in multiple myeloma
Kumar, S. K. (2008) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-008-0015-9 · Cited by 3
“More recently, the use of tandem autologous peripheral blood SCT has led to improved progression-free survival (PFS) and overall survival (OS) compared with single autologous transplantation, particularly in patients failing to achieve at least a very good partial response to initial transplantation [7].”
BackgroundEmerging Therapies for Multiple Myeloma
Podar, K., Hideshima, T., Tai, Y., Richardson, P. G. G., Chauhan, D., & Anderson, K. C. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605030-00001 · Cited by 3
Siddiqui, M. A., & Gertz, M. A. (2008) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190802084972 · Cited by 3
“With a median follow up of 12 years, 15 year EFS was 7%, while 15 year OS was 17% [73].”
BackgroundInitial therapy in multiple myeloma: investigating the new treatment paradigm
Kettle, J. K., Finkbiner, K., Klenke, S. E., Baker, R. D., Henry, D., & Williams, C. B. (2009) · Journal of Oncology Pharmacy Practice · doi:10.1177/1078155208101096 · Cited by 3
Autologous stem-cell transplantation in patients with multiple myeloma.
Stojanoski, Z., Georgievski, B., Cevreska, L. A., Stojanovic, A. T., Pivkova-Veljanovska, A., Genadieva-Stavric, S., Stankovic, S., & Karadzova-Stojanoska, A. (2008) · PubMed · Cited by 3
Role of Bone Marrow Transplantation in the Disease Pathway of Myeloma
Harousseau, J., & Moreau, P. (2007) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2007.0016 · Cited by 3
“The updated results of a Dutch study10 and the preliminary results of 3 other randomized studies also favor double ASCT.11–13 The IFM 94 trial confirmed the feasibility of double ASCT because 75% of patients underwent the second ASCT, and the toxic death rate was less than 5%.9 However, many investigators considered t…”
BackgroundMethodSelf-citationSchnabel, B., Schmidmaier, R., Emmerich, B., & Straka, C. (2006) · Cytotherapy · doi:10.1080/14653240600941531 · Cited by 3
Review Consolidation in multiple myeloma – current status and perspectives
Olszewska‐Szopa, M., & Rzepecki, P. (2014) · Współczesna Onkologia · doi:10.5114/wo.2014.45983 · Cited by 3
“Several years ago, consolidation therapy after ASCT could consist of further ASCT [4].”
BackgroundAutologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Frequently Asked Questions
Mangan, P. A., Gleason, C. L., & Miceli, T. S. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.43-47 · Cited by 3
“One trial showed improved PFS and OS with tandem transplantation compared to single transplantation (Attal et al., 2003).”
BackgroundChen, S. S., Shao, K. N., Chiang, J., Chang, C. Y., Luo, C., Lirng, J. F., & Teng, M. M. (2000) · PubMed · Cited by 3
Gorin, N. C. (2019) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2019.03.025 · Cited by 3
Outcomes of multiple myeloma patients with del 17p undergoing autologous stem cell transplantation
Vaxman, I., Visram, A., Kapoor, P., Kumar, S. K., Dispenzieri, A. A., Buadi, F. K., Dingli, D., Muchtar, E., Gonsalves, W. I., Rajkumar, S. V., et al. (2020) · American Journal of Hematology · doi:10.1002/ajh.26023 · Cited by 3
Introduction: Multiple Myeloma
Cook, R. (2008) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2008.14.s7-a.4 · Cited by 3
Jagannath, S. (2008) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2008.n.027 · Cited by 3
Revisiting the role of dose intensity in hematological malignancies
Holmberg, L., & Stewart, F. M. (2006) · Experimental Hematology · doi:10.1016/j.exphem.2006.04.014 · Cited by 3
Nakashima, Y., Shiratsuchi, M., Abe, Y., Muta, K., Tani, K., Shiokawa, S., & Nishimura, J. (2005) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428190500096708 · Cited by 3
“A randomized study in France showed a significant advantage in the tandem transplantation group based on 7 year EFS and OS against single transplantation [9].”
BackgroundRole of allogeneic stem cell transplantation in multiple myeloma
Thomson, K. J., & Peggs, K. S. (2005) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.5.3.455 · Cited by 3
The Molecular Biology of Multiple Myeloma
Bergsagel, P. L. (2005) · Wiley eBooks · doi:10.1002/9780470987063.ch11 · Cited by 4
Autologous or reduced-intensity conditioning allotransplantation for de novo multiple myeloma
Moreau, P. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.365 · Cited by 2
“2 These results justified prospective trials comparing this autosRIC allo-SCT tandem approach with double auto-SCT, which previously had been shown to be superior to single auto-SCT”
ResultFunctional Cure as a New Concept of Therapy for Multiple Myeloma
Семочкин, С. В. (2025) · Clinical oncohematology · doi:10.21320/2500-2139-2025-18-2-105-120 · Cited by 3
Iacobelli, S., Schönland, S. O., Köster, L., Blaise, D., Nicholson, E., Broers, A. E. C., Chevallier, P., Reményi, P., Folber, F., Gribben, J. G., et al. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02675-2 · Cited by 4
“Several studies investigated tandem auto-HCT to improve outcome after stem cell transplantation, but results are not conclusive [10 – 12].”
Treatment of Multiple Myeloma: Current Management and New Approaches
Ho, P. J., Gibson, J., & Joshua, D. (2004) · American Journal of Cancer · doi:10.2165/00024669-200403010-00005 · Cited by 2
Historical perspective and advances in the treatment of multiple myeloma
Harandi, A., & Laber, D. A. (2008) · Oncology Reviews · doi:10.1007/s12156-008-0082-0 · Cited by 2
“Single vs. Double ASCT [ 28 ] 194 pts age: <60 yrs Single transplant: Advantage of second untreated MM CR + VGPR (42%) 7-yr transplant only seen”
BackgroundRajkumar, S. V. (2012) · Elsevier eBooks · doi:10.1016/b978-1-4377-1604-7.00193-7 · Cited by 4
Transplant Pharmacology and Conditioning Therapy
Bajel, A. R. (2021) · Organ and tissue transplantation · doi:10.1007/978-3-030-36358-1_22 · Cited by 2
Recent Updates on Multiple Myeloma
Al-Anazi, K. A. (2022) · IntechOpen eBooks · doi:10.5772/intechopen.100849 · Cited by 2
Ohno, S., Hayashi, K., Shimizu, R., Ishii, A., & Tanaka, H. (2022) · Journal of the Japan Society of the Reticuloendothelial System · doi:10.3960/jslrt.22013 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2
Malise, T. T. A., Nweke, E. E., Takundwa, M. M., Fru, P., & Raj, D. B. T. G. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_775 · Cited by 2
Jung, J., Jung, S., Lee, J., Do, Y. R., Kang, K., Lee, J. L., Yoon, S., Min, C., Kang, H. J., Lee, J. H., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-74625-9 · Cited by 2
“The IFM92 study randomised 399 patients to receive single or tandem transplantation after induction therapy 5 .”
BackgroundWolf, J., Seymour, F., Parrish, C., Chandler, T., Holt, M., Griffin, J., & Καρακάντζα, Μ. (2025) · Journal of Clinical Apheresis · doi:10.1002/jca.70012 · Cited by 4
Wu, S., Li, X., Qiu, Z., Zhu, Z., Chen, X.-L., Chen, P., Yuan, X., Zhan, R., & Li, N.-N. (2025) · Blood Science · doi:10.1097/bs9.0000000000000235 · Cited by 3
“These results are consistent with those of other studies [4, 11] .”
Oliver, A. C., Pierri, S., Galeano, S., Caneiro, A., Bello, L., Landro, J. D., Miller, A., Gai, R., & Muxi, P. J. (2011) · Revista Médica del Uruguay · Cited by 2
Stojanoski, Z., Georgievski, B., Oliver, K., Sonja, G.-S., Pivkova-Veljanovska, A., & Cevreska, L. A. (2013) · Serbian Journal of Experimental and Clinical Research · doi:10.5937/sjecr14-1882 · Cited by 3
Management Strategies for Relapsed Multiple Myeloma
Richardson, P. G. G., Schlossman, R. L., Munshi, N. C., & Anderson, K. C. (2006) · American Journal of Cancer · doi:10.2165/00024669-200605060-00006 · Cited by 2
Yang, M., Huang, J., Ma, Q., Xu, G., & Jin, J. (2014) · Molecular Medicine Reports · doi:10.3892/mmr.2014.1911 · Cited by 2
Nishihori, T., Kharfan‐Dabaja, M. A., Ochoa-Bayona, J. L., Bazarbachi, A. A., Pasquini, M. C., & Alsina, M. (2011) · Hematology/Oncology and Stem Cell Therapy · doi:10.5144/1658-3876.2011.1 · Cited by 2
Controversies in Multiple Myeloma: to Transplant or Not?
Preeshagul, I. R., van Besien, K., & Mark, T. M. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0230-5 · Cited by 2
Kang, S. H., Hwang, H. S., Park, H. S., Sun, I. O., Choi, S. R., Chung, B. H., Choi, B. S., Yang, C. W., Kim, Y., Min, C., et al. (2011) · Journal of Korean Medical Science · doi:10.3346/jkms.2011.26.10.1310 · Cited by 2
Fatores prognósticos no Mieloma Múltiplo
Martınez, G. (2007) · Revista Brasileira de Hematologia e Hemoterapia · doi:10.1590/s1516-84842007000100007 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Galimberti, S., Boni, R., & Erba, P. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-1 · Cited by 2
Kumar, A., & Djulbegović, B. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp128 · Cited by 3
Double Autologous Stem Cell Transplantation for Multiple Myeloma: A Korean Single Center Study
Ko, O. B., Kim, S., Shim, H., Lee, J.-H., Ahn, J., Yoon, S.-M., Jeon, M., Do, I. N., Lee, S. Y., Kim, Y., et al. (2005) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2005.20.3.237 · Cited by 2
Optimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation
Moreau, P., & Touzeau, C. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.4 · Cited by 2
Wu, K. L., & Sonneveld, P. (2005) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2005.n.035 · Cited by 2
Innovations in autologous transplantation for hematologic malignancy
Forman, S. J. (2005) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2004.11.014 · Cited by 3
Autogreffe de cellules souches hématopoïétiques en hématologie
Boiron, J.-M., Ifrah, N., Hervé, P., & Jouet, J. P. (2006) · Encyclopédie médico-chirurgicale. Hématologie · doi:10.1016/s1155-1984(06)43306-9 · Cited by 2
Primärtherapie beim Multiplen Myelom
Breitkreutz, I., Raab, M., & Goldschmidt, H. (2018) · Der Internist · doi:10.1007/s00108-018-0527-x · Cited by 3
Terpos, E., & Rahemtulla, A. (2005) · Wiley eBooks · doi:10.1002/9780470987056.ch41 · Cited by 2
Biran, N., Rowley, S. D., Vesole, D. H., Zhang, S., Donato, M. L., Skarbnik, A. P. Z., Richter, J. R., Pecora, A. L., & Siegel, D. S. D. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0534-0 · Cited by 2
Charlot-Lambrecht, I., Salmon, J., Gagneux-Lemoussu, L., Brochot, P., & Eschard, J. P. (2012) · EMC - Aparato Locomotor · doi:10.1016/s1286-935x(12)60820-x · Cited by 2
Shain, K. H., & Dalton, W. S. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4666-8_8 · Cited by 2
Radiation Therapy in Multiple Myeloma
Greenberger, J. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_4 · Cited by 2
Dose-Intensive Therapy With Autologous Stem Cell Transplantation for Patients With Multiple Myeloma
Harousseau, J., Attal, M., & Schiller, G. J. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-817-5_9 · Cited by 2
Self-citationRole of stem cell transplantation in myeloma
Gahrton, G., Iacobelli, S., Björkstrand, B., Bourhis, J., Corradini, P., Crawley, C. R., Morris, C., & D. Niederwieser for the European Group (2005) · Hematology · doi:10.1080/10245330512331390168 · Cited by 2
“[3] Attal M, Harousseau JL, Facon T, et al.”
BackgroundTandem Bone Marrow Transplantation in Multiple Myeloma
Murashige, N., & Kishi, Y. (2004) · New England Journal of Medicine · doi:10.1056/nejm200404013501419 · Cited by 2
How can we stamp out high-risk myeloma?
Banerjee, R. K., & Mikhael, J. R. (2024) · Blood · doi:10.1182/blood.2024024140 · Cited by 2
The Current Role of Stem Cell Transplantation in Multiple Myeloma
Gupta, A. K. (2012) · InTech eBooks · doi:10.5772/33242 · Cited by 1
“…al compared single vs. tandem ASCT in 399 patients and found that though the CR rates were equivalent (42 vs. 50%), the 7 year EFS and OS were significantly improved (10% vs. 20% EFS, 21% vs. 42% OS), [35] while the Bologna [36] trial has not shown a significant benefit for tandem transplantation.”
Mochkin, N. E., Sarzhevskiy, V. O., Dubinina, J. N., Smirnova, E. G., Анатольевич, Ф. Д., Bannikova, A. E., Колесникова, Д. С., Сергеевич, Б. В., Samoylova, A. A., Faddeev, N. M., et al. (2020) · Journal of Modern Oncology · doi:10.26442/18151434.2020.2.200179 · Cited by 1
Développements thérapeutiques en hématologie au XXIe siècle
Gorin, N. C. (2022) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2022.07.005 · Cited by 1
Wang, X., Cui, Y., Wang, Y., & Fang, B. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06563-z · Cited by 3
Mel, S. D., Tso, A. C. Y., Soekojo, C. Y., Ooi, M. G. M., Lim, C. C., Teo, C., Chen, Y. X., Tan, M. S. Y., Manjeri, A., Lee, Z. Y., et al. (2025) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202532 · Cited by 1
Autologous stem cell transplantation in the treatment of multiple myeloma single center experience
Marjanović, S., Stamatović, D., Tukić, L., Tarabar, O., Elez, M., Madjaru, L., Balint, B., Tatomirović, Ž., Kuljić-Kapulica, N., & Andjelkovic, N. V. (2011) · Vojnosanitetski pregled · doi:10.2298/vsp1105387m · Cited by 1
Multiple myeloma – current status and future directions
Rasche, L., & Knop, S. T. (2013) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2013.841577 · Cited by 1
“Before the introduction of the novel compounds, two sequentially performed high dose therapies (‘tandem transplantation’) were shown to be superior to single transplantation in a randomised trial [30].”
BackgroundTriple MEL100 Therapy in Multiple Myeloma
Berz, D., Colvin, G. A., McCormack, E. M., Winer, E. S., Karwan, P., Colvin, L., Rathore, R., Lum, L. G., Elfenbein, G. J., & Quesenberry, P. J. (2009) · Transplantation Proceedings · doi:10.1016/j.transproceed.2009.06.196 · Cited by 1
Wiesmann, A., Einsele, H., Kanz, L., & Dohmen, B. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1705002 · Cited by 1
Metadata
- Authors
- Attal, M., Harousseau, J.-L., Facon, T., Guilhot, F., Doyen, C., Fuzibet, J.-G., Monconduit, M., Hulin, C., Caillot, D., Bouabdallah, R., Voillat, L., Sotto, J.-J., Grosbois, B., & Bataille, R.
- Affiliations
- Hôpital Purpan (FR)
- Hôpital Claude Huriez (FR)
- Centre Hospitalier Universitaire de Poitiers (FR)
- Centre Hospitalier Universitaire de Nice (FR)
- Centre Henri Becquerel (FR)
- Centre Hospitalier Régional et Universitaire de Nancy (FR)
- CHU Dijon Bourgogne (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Hôpital Albert Michallon (FR)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-12-25
- Volume
- 349
- Issue
- 26
- Pages
- 2495-2502
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1982499121
- Cited by
- 984
- References
- 16
- Citations by year
- 2026: 3 · 2025: 13 · 2024: 18 · 2023: 14 · 2022: 22 · 2021: 20 · 2020: 33 · 2019: 18 · 2018: 35 · 2017: 28 · 2016: 24 · 2015: 37 · 2014: 38 · 2013: 53 · 2012: 42
- FWCI
- 34.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Digital Access to Libraries (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, autologous stem cell transplantation, high-dose chemotherapy, overall survival, event-free survival, very good partial response, beta2-microglobulin, lactate dehydrogenase, prognostic factors
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Dexamethasone, Doxorubicin, Female, Humans, Male, Middle Aged, Multiple Myeloma, Neoplasm Staging, Prognosis, Transplantation, Autologous, Vincristine, Survival Rate, Multivariate Analysis, Hematopoietic Stem Cell Transplantation, Disease-Free Survival, Transplantation Conditioning
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.